Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research
  Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login  
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 590    

   Table of Contents      
Year : 2015  |  Volume : 142  |  Issue : 1  |  Page : 23-32

Alterations of mucosal microbiota in the colon of patients with inflammatory bowel disease revealed by real time polymerase chain reaction amplification of 16S ribosomal ribonucleic acid

Wellcome Trust Research Laboratory, Christian Medical College, Vellore, India

Date of Submission22-Jul-2013
Date of Web Publication4-Aug-2015

Correspondence Address:
Balakrishnan S Ramakrishna
Wellcome Trust Research Laboratory, Christian Medical College, Vellore 632 004, Tamil Nadu
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0971-5916.162091

Rights and Permissions

Background & objectives: Alterations in microbial communities closely associated with the intestinal mucosa are likely to be important in the pathogenesis of inflammatory bowel disease (IBD). We examined the abundance of specific microbial populations in colonic mucosa of patients with ulcerative colitis (UC), Crohn's disease (CD) and controls using reverse transcription quantitative polymerase chain reaction (RT-qPCR) amplification of 16S ribosomal ribonucleic acid (16S rRNA).
Methods: RNA was extracted from colonic mucosal biopsies of patients with UC (32), CD (28) and patients undergoing screening colonoscopy (controls), and subjected to RT-qPCR using primers targeted at 16S rRNA sequences specific to selected microbial populations.
Results: Bacteroides-Prevotella-Porphyromonas group and Enterobacteriaceae were the most abundant mucosal microbiota. Bacteroides and Lactobacillus abundance was greater in UC patients compared with controls or CD. Escherichia coli abundance was increased in UC compared with controls. Clostridium coccoides group and C. leptum group abundances were reduced in CD compared with controls. Microbial population did not differ between diseased and adjacent normal mucosa, or between untreated patients and those already on medical treatment. The Firmicutes to Bacteroidetes ratio was significantly decreased in both UC and CD compared with controls, indicative of a dysbiosis in both conditions.
Interpretation & conclusions: Dysbiosis appears to be a primary feature in both CD and UC. Microbiome-directed interventions are likely to be appropriate in therapy of IBD.

Keywords: Bacteroidetes - Crohn′s disease - dysbiosis - Firmicutes - microbiota - ulcerative colitis

How to cite this article:
Kabeerdoss J, Jayakanthan P, Pugazhendhi S, Ramakrishna BS. Alterations of mucosal microbiota in the colon of patients with inflammatory bowel disease revealed by real time polymerase chain reaction amplification of 16S ribosomal ribonucleic acid. Indian J Med Res 2015;142:23-32

How to cite this URL:
Kabeerdoss J, Jayakanthan P, Pugazhendhi S, Ramakrishna BS. Alterations of mucosal microbiota in the colon of patients with inflammatory bowel disease revealed by real time polymerase chain reaction amplification of 16S ribosomal ribonucleic acid. Indian J Med Res [serial online] 2015 [cited 2021 Sep 20];142:23-32. Available from:

The inflammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn's disease (CD) is thought to represent abnormal innate inflammatory reactions occurring in response to normal constituents of the gut microbiota in genetically predisposed individuals. The gut contains trillions of microbes which affect human health in many ways through effects on nutrition, metabolism and immunity [1] . The gut microbiota influence innate and adaptive immune responses in the intestine. Some of the microbial populations dampen immune and inflammatory responses through amplification of regulatory immune cells, while others induce inflammatory reactions [2] . IBD has been associated with a breakdown in the balance between putative species of protective versus harmful intestinal bacteria, a phenomenon that has been termed dysbiosis [3] .

Most of the studies on dysbiosis in IBD have examined the balance of specific microbial populations in the faeces. While the bulk of the gastrointestinal microbiota reside within the lumen, the subset that resides in the outer mucus layer covering the epithelial surface is likely to be most important in the gut microbial interaction with the innate immune system [4] , and therefore, it is most likely to have a bearing on the pathogenesis of IBD. Several studies, including one from India, have examined colonic mucosal bacterial populations in IBD and demonstrated alterations in the balance between putative beneficial and harmful bacterial populations [5],[6] . The mucosa-associated bacteria are difficult to study because of their low numbers. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) targeting 16S ribosomal RNA (rRNA) molecules is more than 100-fold sensitive and specific than qPCR alone in quantitating the microbial population because of the high copy number of targeted rRNA molecules [7] . Moreover, measuring 16s rRNA rather than the DNA (16S rRNA gene) identifies actively transcribing bacteria, which are more likely to affect intestinal immune reactions and thus have a greater bearing on human health than inactive or dead bacteria [8] .

The primary objective of the present study was to determine whether there were alterations in specific actively transcribing bacterial populations in the colonic mucosa of IBD patients compared to control volunteers. The secondary objectives were to determine whether there were differences in the actively transcribing bacterial populations between normal and abnormal mucosa of IBD patients, and to determine whether the balance and distribution of the microbial populations were influenced by the severity of mucosal inflammation or by medical therapy.

   Material & Methods Top

The participants were recruited from the Gastroenterology and Inflammatory Bowel Disease clinics of the Christian Medical College, Vellore, Tamil Nadu, India, from December 2008 to December 2010. Consecutive patients with IBD undergoing colonoscopy were recruited as the case group, while controls were recruited from patients with haemorrhoidal bleeding referred for colonoscopy to exclude neoplasia. IBD diagnosis and characterization was based on standard consensus criteria [9] . Patients were investigated as per the usual clinical protocol of the department.

The participants provided written informed consent for the additional biopsies that were taken for study. The study protocol was approved by the Institutional Review Board of the Christian Medical College, Vellore.

Colonoscopies were performed after colonic lavage using orally administered polyethylene glycol-electrolyte solution. Mucosal biopsy samples were obtained using standard biopsy forceps from endoscopically normal mucosa of the colon in controls and from abnormal or ulcerated mucosa in patients with IBD. In patients with CD and in UC patients with limited disease, apparently normal mucosa at least 5 cm from endoscopically abnormal areas was also biopsied for the study. Mucosal biopsies were immediately washed in sterile saline, snap-frozen in liquid nitrogen, and stored at -80°C until processing. Zoetendal et al[10] examined mucosal biopsies from different regions of the colon and showed that the mucosal bacterial community in the human colon was uniformly distributed throughout the colon with little variation by location. In our study, since biopsies from IBD patients included both normal and ulcerated mucosa from different regions of the colon, the normal and ulcerated biopsies were matched by region of the colon.

Reverse transcriptase quantitative polymerase chain reaction (RT-qPCR): RNA was extracted from the biopsies using Tri reagent (Sigma, USA), following manufacturer's instructions. RNA concentration in the samples were measured by spectrometry (Nanodrop, Thermo Scientific, USA). RNA samples (250 ng per biopsy sample) were converted to cDNA, using reverse transcriptase core kit (Eurogentec, Liege, Belgium). RNase pretreatment was not used [7] . The reverse transcription reaction mix was prepared on ice and contained final concentration of 1X buffer, 5mM MgCl 2, 500 μM of each deoxy nucleotide phosphate (dNTPs), 2.5 μM random nonamer, 0.4 U/μl of RNAse inhibitor, 1.25 U/μl of EuroScript RT, 250 ng of total RNA and RNase free water to adjust the final volume to 10 μl. The cDNA conversion was carried out in a PTC-150 MiniCycler (MJ Research, USA) using a cycling protocol with an initial step for 10 min at

25 °C, followed by a reverse transcriptase step for 30 min at 48 °C and a final inactivation step for 5 min at

95 °C.

Diluted cDNA samples were then amplified in quantitative PCR. Amplification and detection were carried out in 96-well plates with Mesa Green qPCR MasterMix Plus for SYBR ® Assay I dTTP (Catalog number RT-SY2X-03+NR WOUN, Eurogentec, Liege, Belgium) to quantify total bacteria and the specific bacterial populations listed in [Table 1]. Each reaction was done in duplicate in a final volume of 20 µl with 2X MasterMix, 250 nM final concentration of each primer, and 2 µl of DNA sample. Quantification was performed in a real time PCR instrument, the Chromo 4 thermocycler coupled to a fluorescence detector (Biorad, USA) under the following conditions: initial denaturation at 95°C for 5 min followed by 45 cycles of 95°C for 20 sec, annealing temperature as shown in [Table 2] for each bacterial population, and final elongation at 72°C for 30 sec. Fluorescence quantitation was analyzed using the Opticon monitor system software v. 3 (Biorad, USA). A dissociation step was added and melting curves were analyzed to confirm the identity and fidelity of amplification of SYBR Green products.
Table 1. Primers used in this study and amplicon sizes

Click here to view
Table 2. Demographic and clinical characteristics of participants

Click here to view

Details of the 16S rRNA-targeted primers used in this study and their specificities are described in [Table 1] [11],[12],[13],[14],[15],[16],[17],[18] . These primers were purchased from Bioserve Biotechnologies (Hyderabad, India). The Opticon 3.1 (BioRad, Hercules, CA, USA) software, provided with the instrument, plotted the rate of change of the relative fluorescence units (RFU) with reference to time (T) (-d (RFU)/dT) on the Y-axis versus the temperature on the X-axis, with the curve peaking at the melting temperature. Quantification was based on the fluorescence intensity obtained from the intercalated SYBR Green dye. The cycle number at which the signal was first detected - the threshold cycle (Ct) - correlated with the original concentration of DNA template. DNA copy was not expressed as absolute number but was expressed as the relative abundance of the specified microbial population, being calculated from the Ct at which DNA for each target bacterial population was detected relative to the Ct at which universal bacterial DNA was detected during amplification, using the formula 2-ΔCt , where ΔCt = Ct [Bacteria of interest] - Ct [Universal bacteria], and expressed by the software as the relative fold difference. This relative quantification was done automatically by the Opticon 3.1 software. The relative abundance of the target bacterial population was thus the ratio of the target bacterial rRNA compared to universal rRNA, providing a quantitative comparison between different samples. The ratio calculated for each of the duplicate samples always correlated well with the other, with an adjusted R [2] in the region of 0.80 [11] .

Statistical analysis: The quantitative PCR was done with two technical replicates for each sample. The mean of the relative difference was taken for duplicate. The relative difference for each bacterial population in each study group (UC, CD, control) was expressed as mean±SEM, and the significance of differences between groups was assessed using unpaired t test with Welch correction for unequal variances.

   Results Top

Thirty control participants, 28 patients with CD and 32 patients with UC were included in the study. Their demographic and clinical characteristics are described in [Table 2].

Differences in mucosal microbiota between controls and IBD patients: The two major microbial communities associated with the mucosa were the Bacteroides-Prevotella-Porphyromonas group and the family Enterobacteriaceae. The Bacteroides-Prevotella-Porphyromonas group was significantly more abundant in UC compared with controls as well as CD [Figure 1]. Enterobacteriaceae, a major aerobic bacterial group, was not significantly different between the groups. However Escherichia coli, a constituent of Enterobacteriaceae, was significantly more abundant in the mucosa of patients with UC. Lactobacillus group bacteria were also significantly increased in UC compared with controls or CD [Figure 1]. Clostridium coccoides-Eubacterium rectale group was significantly less abundant in CD mucosa compared with controls and Clostridium leptum group was significantly less abundant in CD compared to UC mucosa [Figure 1]. The other microbial populations tested were not significantly different between the study groups.
Figure 1. Quantitative representation of the various mucosa-associated bacterial populations in controls, patients with Crohn's disease (CD) and patients with ulcerative colitis (UC). The bars represent mean ± SEM of the relative difference which is the fold amplification of sequences for the target population relative to amplification of universal bacterial domain sequences. significant differences (ANOVA with post-hoc Dunnett's test) are shown.

Click here to view

Differences in mucosal microbiota between normal and inflamed areas of the colon: Mucosal inflammation or ulceration may potentially alter the abundance of microbial population by altering the microenvironment necessary for the association of these microbiota with the mucosa. TheThe relative abundance of mucosal microbiota between normal and inflamed colonic mucosa was compared in patients with IBD [Figure 2]. In 24 patients with CD, paired biopsies were available from both normal and inflamed areas of the colon. There were no significant differences in microbiota composition between normal and inflamed areas [Table 3]. Paired biopsies from normal and inflamed areas were available in 18 patients with UC. Again, there were no significant difference in microbiota composition between normal and inflamed mucosa [Table 3].
Figure 2. Bacterial populations in ulcerated and normal colonic mucosa of patients with Crohn's disease (CD) and ulcerative colitis (UC). Bars represent mean ± SEM of the relative difference (fold amplification with reference to amplification of universal bacterial domain sequences). None of the differences between normal and ulcerated mucosa for each bacterial population was significant.

Click here to view
Table 3. Bacterial populations in biopsies from normal areas and from inflamed areas in patients with Crohn's disease and ulcerative colitis

Click here to view

Effect of prior treatment on mucosal bacteria in IBD: Medical therapy of IBD can potentially alter microbiota composition. We compared mucosal bacteria in treatment-naïve IBD (CD and UC) patients with those who were receiving treatment at the time of biopsy. There were no significant differences in the mucosal microbiota between the two groups, except for Clostridium coccoides-Eubacterium rectale that was significantly more abundant in patients on therapy [Figure 3].
Figure 3. Bacterial populations in ulcerated mucosa of treatment-naïve or treated patients with IBD. Bars represent mean ± SEM of the relative difference which is the fold amplification of sequences for the target population relative to amplification of universal bacterial domain sequences. significant differences (unpaired t test with Welch's correction) are indicated in the Figure. Bacteroides-Prevotella-Porphyromonas and Enterobacteriaceae are depicted on the left Y-axis; the remaining bacterial populations are depicted on the right Y-axis. BP, Bacteroides-prevotella-Porphyromonas; EB, Enterobacteriaceae ; BB, Bifidobacteria; CL, Clostridium leptum; CC, Clostridium coccoides; LB, Lactobacillus.

Click here to view

Ratio of Firmicutes to Bacteroidetes in the mucosa: Clostridium coccoides-Eubacterium rectale (cluster XIV) and Clostridium leptum (cluster IV) groups represent the major constituents of phylum Firmicutes among the colonic microbiota, while Bacteroides-Prevotella-Porphyromonas group represents the major constituent of phylum Bacteroidetes in the colonic microbiota. The ratio of Firmicutes to Bacteroidetes has been used to express the degree of dysbiosis in IBD. We, therefore, examined the ratio of Clostridium (sum of the two Clostridium clusters measured) to Bacteroides among the mucosal microbiota as a measure of dysbiosis. This ratio was significantly reduced in both forms of IBD, in both inflamed and normal mucosa, and regardless of treatment [Figure 4].
Figure 4. Ratio of Firmicutes (C. coccoides plus C. leptum) to Bacteroidetes in the mucosal microbiota. The Figure shows the ratio in patients with CD and UC. CD-N and CD-Ab refer to Crohn's disease normal and abnormal mucosa. UC-N and UC-Ab refer to ulcerative colitis normal and abnormal mucosa. Significant P values are shown above the bars in the Figure. None of the other differences was significant. IBD biopsies showed a significantly lower ratio compared with controls.

Click here to view

   Discussion Top

We report that Bacteroides-Prevotella-Porphyromonas and Enterobacteriaceae were the most abundant microbial population associated with the colonic mucosa. By contrast, Firmicutes (principally clostridia) which are the most abundant constituents of the colonic luminal microbiota, were much less abundant in the mucosa. Importantly, our findings confirmed the existence of a dysbiosis in the mucosa in IBD patients that did not appear to be secondary to the presence of mucosal inflammation.

Clostridium coccoides group, including Eubacterium rectale, constitutes Clostridium cluster XIV, while Clostridium leptum group, including Faecalibacterium prausnitzii, is the major constituent of Clostridium cluster IV. Changes described in the faeces in CD include reductions in number of bacteria belonging to these two clusters, which are important in carbohydrate fermentation and short chain fatty acid (particularly butyrate) production [19] . Changes described in the faecal microbiota, at the phylum level, include increased abundance of Bacteroidetes and Proteobacteria, and reduced abundance of Firmicutes in the faeces of patients with CD [20] .

In contrast to the above studies of faecal microbiota, studies of the mucosal microbiota in IBD have used a variety of approaches and resulted in variable findings. Invasive-adherent E. coli have been reported in the ileal mucosal biopsies of patients with ileal CD [21] . Hartley et al[22] isolated greater numbers of Bacteroides species from rectal biopsies of patients with active UC than from patients with inactive disease. Using molecular techniques, Bibiloni et al[23] reported an increase in unclassified bacteria belonging to phylum Bacteroidetes in biopsies from CD patients and an increase in Porphyromonas species in biopsies from UC patients. Verma et al[5] showed that Bacteroidetes population decreased in IBD patients compared to controls. In the present study, Bacteroides-Prevotella-Porphyromonas group was increased in the mucosa of UC patients compared with CD and controls. The differences between the two studies, both based in India, are likely to reflect the use of different primers to quantitate the bacterial population in these two studies. As in the above Indian study [5] , we also found decrease in the numbers of Clostridium in the mucosa of patients with CD. Swidsinki et al[24] investigated the mucosal bacteria by in situ hybridization in biopsies where the mucus layer was retained, and found reduced abundance of bacteria belonging to the C. coccoides-E. rectale group and increased abundance of Bacteroides in patients with IBD compared to those with irritable bowel syndrome. Reduced abundance of Faecalibacterium prausnitzii in ileocolonic mucosal biopsies from patients with CD has also been reported [25] . Increased populations of phylum Bacteroidetes and reduced populations of phylum Firmicutes in the mucosa of IBD, especially CD, patients have also been reported. Quantitation of 16S rRNA in mucosal biopsies suggested that

E. coli were both abundant and transcriptionally very active in both forms of IBD, while transcription of Actinobacteria and Firmicutes was suppressed in CD [26] . The present study was generally consistent with the above studies, showing an increase in the relative abundance of Bacteroides and E. coli in the mucosa of UC patients and decrease in relative abundance of Clostridium clusters XIV and IV in CD. Differences between studies may relate to differences in techniques for identification and quantitation, differences in diet of the individuals, and to restricted sample sizes in some studies.

The present study did not find significant differences in the mucosa-associated bacteria between apparently normal and inflamed mucosa in patients with IBD. In an earlier study comparing ulcerated and non-ulcerated mucosa in CD and UC, increases in Bacteroidetes and reduction in Firmicutes were more likely to be observed in ulcerated mucosa than in non-ulcerated mucosa; however, the numbers studied were small and there was considerable inter-individual variability [27] . In another study, bacterial community diversity was found to be less in ulcerated mucosa compared to non-ulcerated mucosa; however, that study did not attempt to generate microbial quantitative data [28] . The present study used RT-qPCR to quantitate specific microbial populations, and did not show significant differences in relative microbial abundance between ulcerated and non-ulcerated areas.

Bacteroides are important commensal bacteria that have been implicated in the pathogenesis of inflammatory bowel disease [29] . On the other hand, microbes belonging to the Clostridium clusters XIV and IV are important and major constituents of the normal colonic microbiota. The alteration in the ratio between Clostridium species which are considered beneficial and Bacteroides which are considered aggressive, is an indicator of dysbiosis in patients with IBD. The Firmicutes to Bacteroidetes ratio in faeces is very similar to the above and has been considered as an indicator of human gut microbiota status. An increase in Firmicutes characterizes obesity [1] while an increase in Bacteroidetes has been reported to occur with ageing [30] . While one study suggests that the ratio of Faecalibacterium prausnitzii to E. coli is the important factor in dysbiosis, it is possible that the specific microbial imbalance may vary in different communities and countries. Understanding this better will obviously be of importance when considering therapies to counter dysbiosis. Another study done from north India which looked at mucosal microbiota in ulcerated areas, did not examine bacterial populations in normal mucosa of IBD patients [5] .

In conclusion, there were alterations in the mucosa-associated microbiota in both UC and CD characterized by reduction in abundance of microbes belonging to phylum Firmicutes relative to microbes belonging to phylum Bacteroidetes. The microbial populations did not significantly differ between normal and inflamed mucosa or between untreated and treated patients. These findings suggested that dysbiosis was a primary feature of both forms of IBD and that microbiome-directed interventions could be appropriate targets for therapy of IBD.

Conflicts of interest: None.

   References Top

Ramakrishna BS. Role of the gut microbiota in human nutrition and metabolism. J Gastroenterol Hepatol 2013; 28 (Suppl 4): 9-17.  Back to cited text no. 1
Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI. Human nutrition, the gut microbiome and the immune system. Nature 2011; 474 : 327-36.  Back to cited text no. 2
Kaur N, Chen CC, Luther J, Kao JY. Intestinal dysbiosis in inflammatory bowel disease. Gut Microbes 2011; 2 : 211-6.  Back to cited text no. 3
Johansson ME, Larsson JM, Hansson GC. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci USA 2011; 108 (Suppl 1) : 4659-65.  Back to cited text no. 4
Verma R, Verma AK, Ahuja V, Paul J. Real-time analysis of mucosal flora in patients with inflammatory bowel disease in India. J Clin Microbiol 2010; 48 : 4279-82.  Back to cited text no. 5
Walker AW, Sanderson JD, Churcher C, Parkes GC, Hudspith BN, Rayment N, et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol 2011; 11 : 7.  Back to cited text no. 6
Matsuda K, Tsuji H, Asahara T, Matsumoto K, Takada T, Nomoto K. Establishment of an analytical system for the human fecal microbiota, based on reverse transcription-quantitative PCR targeting of multicopy rRNA molecules. Appl Environ Microbiol 2009; 75 : 1961-9.  Back to cited text no. 7
Sokol H, Lepage P, Seksik P, Doré J, Marteau P. Temperature gradient gel electrophoresis of fecal 16S rRNA reveals active Escherichia coli in the microbiota of patients with ulcerative colitis. J Clin Microbiol 2006; 44 : 3172-7.  Back to cited text no. 8
Ouyang Q, Tandon R, Goh KL, Pan GZ, Fock KM, Fiocchi C, et al. Management consensus of inflammatory bowel disease for the Asia-Pacific region. J Gastroenterol Hepatol 2006; 21 : 1772-82.  Back to cited text no. 9
Zoetendal EG, von Wright A, Vilpponen-Salmela T, Ben-Amor K, Akkermans AD, de Vos WM. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl Environ Microbiol 2002; 68 : 3401-7.  Back to cited text no. 10
Balamurugan R, Janardhan HP, George S, Raghava MV, Muliyil J, Ramakrishna BS. Molecular studies of fecal anaerobic commensal bacteria in acute diarrhea in children. J Pediatr Gastroenterol Nutr 2008; 46 : 514-9.  Back to cited text no. 11
Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermudez-Humaran LG, Gratadoux JJ, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008; 105 : 16731-6.  Back to cited text no. 12
Ahmed S, Macfarlane GT, Fite A, McBain AJ, Gilbert P, Macfarlane S. Mucosa-associated bacterial diversity in relation to human terminal ileum and colonic biopsy samples. Appl Environ Microbiol 2007; 73 : 7435-42.  Back to cited text no. 13
Rinttila T, Kassinen A, Malinen E, Krogius L, Palva A. Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR. J Appl Microbiol 2004; 97 : 1166-77.  Back to cited text no. 14
Matsuki T, Watanabe K, Fujimoto J, Kado Y, Takada T, Matsumoto K, et al. Quantitative PCR with 16S rRNA-gene-targeted species-specific primers for analysis of human intestinal bifidobacteria. Appl Environ Microbiol 2004; 70 : 167-73.  Back to cited text no. 15
Balamurugan R, Rajendiran E, George S, Samuel GV, Ramakrishna BS. Real-time polymerase chain reaction quantification of specific butyrate-producing bacteria, Desulfovibrio and Enterococcus faecalis in the feces of patients with colorectal cancer. J Gastroenterol Hepatol 2008; 23 : 1298-303.  Back to cited text no. 16
Huijsdens XW, Linskens RK, Mak M, Meuwissen SG, Vandenbroucke-Grauls CM, Savelkoul PH. Quantification of bacteria adherent to gastrointestinal mucosa by real-time PCR. J Clin Microbiol 2002; 40 : 4423-7.  Back to cited text no. 17
Lay C, Sutren M, Rochet V, Saunier K, Dore J, Rigottier-Gois L. Design and validation of 16S rRNA probes to enumerate members of the Clostridium leptum subgroup in human faecal microbiota. Environ Microbiol 2005; 7 : 933-46.  Back to cited text no. 18
Kang S, Denman SE, Morrison M, Yu Z, Dore J, Leclerc M, et al. Dysbiosis of fecal microbiota in Crohn's disease patients as revealed by a custom phylogenetic microarray. Inflamm Bowel Dis 2010; 16 : 2034-42.  Back to cited text no. 19
Joossens M, Huys G, Cnockaert M, De Preter V, Verbeke K, Rutgeerts P, et al. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 2011; 60 : 631-7.  Back to cited text no. 20
Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004; 127 : 412-21.  Back to cited text no. 21
Hartley MG, Hudson MJ, Swarbrick ET, Hill MJ, Gent AE, Hellier MD, et al. The rectal mucosa-associated microflora in patients with ulcerative colitis. J Med Microbiol 1992; 36 : 96-103.  Back to cited text no. 22
Bibiloni R, Mangold M, Madsen KL, Fedorak RN, Tannock GW. The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. J Med Microbiol 2006; 55 : 1141-9.  Back to cited text no. 23
Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 2005; 43 : 3380-9.  Back to cited text no. 24
Martinez-Medina M, Aldeguer X, Gonzalez-Huix F, Acero D, Garcia-Gil LJ. Abnormal microbiota composition in the ileocolonic mucosa of Crohn's disease patients as revealed by polymerase chain reaction-denaturing gradient gel electrophoresis. Inflamm Bowel Dis 2006; 12 : 1136-45.  Back to cited text no. 25
Rehman A, Lepage P, Nolte A, Hellmig S, Schreiber S, Ott SJ. Transcriptional activity of the dominant gut mucosal microbiota in chronic inflammatory bowel disease patients. J Med Microbiol 2010; 59 : 1114-22.  Back to cited text no. 26
Walker AW, Sanderson JD, Churcher C, Parkes GC, Hudspith BN, Rayment N, et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol 2011; 11 : 7.  Back to cited text no. 27
Li Q, Wang C, Tang C, Li N, Li J. Molecular-phylogenetic characterization of the microbiota in ulcerated and non-ulcerated regions in the patients with Crohn's disease. PLoS One 2012; 7 : e34939.  Back to cited text no. 28
Bloom SM, Bijanki VN, Nava GM, Sun L, Malvin NP, Donermeyer DL, et al. Commensal Bacteroides species induce colitis in host-genotype-specific fashion in a mouse model of inflammatory bowel disease. Cell Host Microbe 2011; 9 : 390-403.  Back to cited text no. 29
Mariat D, Firmesse O, Levenez F, Guimaraes V, Sokol H, Dore J, et al. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol 2009; 9 : 123.  Back to cited text no. 30


  [Figure 1], [Figure 2], [Figure 3], [Figure 4]

  [Table 1], [Table 2], [Table 3]

This article has been cited by
1 Temporal Dynamics of Chronic Inflammation on the Cecal Microbiota in IL-10-/- Mice
Anne-Marie C. Overstreet,Amanda E. Ramer-Tait,Jan S. Suchodolski,Jesse M. Hostetter,Chong Wang,Albert E. Jergens,Gregory J. Phillips,Michael J. Wannemuehler
Frontiers in Immunology. 2021; 11
[Pubmed] | [DOI]
2 Systematic Review: The Gut Microbiome and Its Potential Clinical Application in Inflammatory Bowel Disease
Laila Aldars-García,María Chaparro,Javier P. Gisbert
Microorganisms. 2021; 9(5): 977
[Pubmed] | [DOI]
3 Blastocystis Colonization Alters the Gut Microbiome and, in Some Cases, Promotes Faster Recovery From Induced Colitis
Vincent Billy,Zuzana Lhotská,Milan Jirku,Oldriška Kadlecová,Lucia Frgelecová,Laura Wegener Parfrey,Katerina Jirku Pomajbíková
Frontiers in Microbiology. 2021; 12
[Pubmed] | [DOI]
4 Alterations in Gut Microbial Communities Across Anatomical Locations in Inflammatory Bowel Diseases
Youlian Zhou,Yan He,Le Liu,Wanyan Zhou,Pu Wang,Han Hu,Yuqiang Nie,Ye Chen
Frontiers in Nutrition. 2021; 8
[Pubmed] | [DOI]
5 Single Donor FMT Reverses Microbial/Immune Dysbiosis and Induces Clinical Remission in a Rat Model of Acute Colitis
Petra Adamkova,Petra Hradicka,Sona Gancarcikova,Monika Kassayova,Lubos Ambro,Izabela Bertkova,Martin Maronek,Silvia Farkasova Iannaccone,Vlasta Demeckova
Pathogens. 2021; 10(2): 152
[Pubmed] | [DOI]
6 Effects of a Rice Bran Dietary Intervention on the Composition of the Intestinal Microbiota of Adults with a High Risk of Colorectal Cancer: A Pilot Randomised-Controlled Trial
Winnie K. W. So,Judy Y. W. Chan,Bernard M. H. Law,Kai Chow Choi,Jessica Y. L. Ching,Kam Leung Chan,Raymond S. Y. Tang,Carmen W. H. Chan,Justin C. Y. Wu,Stephen K. W. Tsui
Nutrients. 2021; 13(2): 526
[Pubmed] | [DOI]
7 Bioactive Compounds in Food as a Current Therapeutic Approach to Maintain a Healthy Intestinal Epithelium
Eva Salinas,Diana Reyes-Pavón,Naima G. Cortes-Perez,Edgar Torres-Maravilla,Oscar K. Bitzer-Quintero,Philippe Langella,Luis G. Bermúdez-Humarán
Microorganisms. 2021; 9(8): 1634
[Pubmed] | [DOI]
8 Porphyromonas gingivalis outside the oral cavity
Steeve Bregaint,Emile Boyer,Shao Bing Fong,Vincent Meuric,Martine Bonnaure-Mallet,Anne Jolivet-Gougeon
Odontology. 2021;
[Pubmed] | [DOI]
9 Dysbiosis in the Salivary Microbiome Associated with IgA Nephropathy—?A? ?Japanese Cohort Study
Anushka Khasnobish,Lena Takayasu,Ken-ichi Watanabe,Tien Thi Thuy Nguyen,Kensuke Arakawa,Osamu Hotta,Kensuke Joh,Akiyo Nakano,Shuhei Hosomi,Masahira Hattori,Wataru Suda,Hidetoshi Morita
Microbes and Environments. 2021; 36(2): n/a
[Pubmed] | [DOI]
10 Kaempferol Alleviates Murine Experimental Colitis by Restoring Gut Microbiota and Inhibiting the LPS-TLR4-NF-?B Axis
Yifan Qu,Xinyi Li,Fengying Xu,Shimin Zhao,Xuemei Wu,Yuzhen Wang,Jiming Xie
Frontiers in Immunology. 2021; 12
[Pubmed] | [DOI]
11 Characterization of the gut microbiota in patients with primary sclerosing cholangitis compared to inflammatory bowel disease and healthy controls
Samaneh Ostadmohammadi,Masoumeh Azimirad,Hamidreza Houri,Kaveh Naseri,Ehsan Javanmard,Hamed Mirjalali,Abbas Yadegar,Amir Sadeghi,Hamid Asadzadeh Aghdaei,Mohammad Reza Zali
Molecular Biology Reports. 2021;
[Pubmed] | [DOI]
12 Seasonal changes of circulating 25-hydroxyvitamin D correlate with the lower gut microbiome composition in inflammatory bowel disease patients
Katarina Soltys,Martina Stuchlikova,Tibor Hlavaty,Barbora Gaalova,Jaroslav Budis,Juraj Gazdarica,Anna Krajcovicova,Zuzana Zelinkova,Tomas Szemes,Daniel Kuba,Hana Drahovska,Jan Turna,Stanislav Stuchlik
Scientific Reports. 2020; 10(1)
[Pubmed] | [DOI]
13 Berberine improves colitis by triggering AhR activation by microbial tryptophan catabolites
Wanghui Jing,Sijing Dong,Xialin Luo,Jingjing Liu,Bin Wei,Wei Du,Lin Yang,Hua Luo,Yitao Wang,Sicen Wang,Haitao Lu
Pharmacological Research. 2020; : 105358
[Pubmed] | [DOI]
14 The Influence of Probiotics on the Firmicutes/Bacteroidetes Ratio in the Treatment of Obesity and Inflammatory Bowel disease
Spase Stojanov,Aleš Berlec,Borut Štrukelj
Microorganisms. 2020; 8(11): 1715
[Pubmed] | [DOI]
15 Microbiota insights in Clostridium difficile infection and inflammatory bowel disease
C. Rodríguez,E. Romero,L. Garrido-Sanchez,G. Alcaín-Martínez,RJ. Andrade,B. Taminiau,G. Daube,E. García-Fuentes
Gut Microbes. 2020; : 1
[Pubmed] | [DOI]
16 The Effectiveness of Multi-Session FMT Treatment in Active Ulcerative Colitis Patients: A Pilot Study
Dorota Mankowska-Wierzbicka,Marta Stelmach-Mardas,Marcin Gabryel,Hanna Tomczak,Marzena Skrzypczak-Zielinska,Oliwia Zakerska-Banaszak,Anna Sowinska,Dagmara Mahadea,Alina Baturo,Lukasz Wolko,Ryszard Slomski,Agnieszka Dobrowolska
Biomedicines. 2020; 8(8): 268
[Pubmed] | [DOI]
17 Changes in intestinal microbiota and correlation with TLRs in ulcerative colitis in the coastal area of northern China
Ning Xu,Xuelian Bai,Xiaoling Cao,Wenjing Yue,Weiwei Jiang,Zhenhai Yu
Microbial Pathogenesis. 2020; : 104707
[Pubmed] | [DOI]
18 Dynamic Changes in the Gut Microbiome at the Acute Stage of Ischemic Stroke in a Pig Model
Julie Jeon,Jeferson Lourenco,Erin E. Kaiser,Elizabeth S. Waters,Kelly M. Scheulin,Xi Fang,Holly A. Kinder,Simon R. Platt,Michael J. Rothrock,Todd R. Callaway,Franklin D. West,Hea Jin Park
Frontiers in Neuroscience. 2020; 14
[Pubmed] | [DOI]
19 Zerumbone Restores Gut Microbiota Composition in ETBF Colonized AOM/DSS Mice
Hye-Won Cho,Ki-Jong Rhee,Yong-Bin Eom
Journal of Microbiology and Biotechnology. 2020; 30(11): 1640
[Pubmed] | [DOI]
20 Intestinal microbiocenosis in patients with recurrent Clostridium difficile infection, ulcerative colitis and irritable bowel syndrome after transplantation of fecal microflora
E. V. Shrainer,A. I. Khavkin,V. V. Vlasov
Experimental and Clinical Gastroenterology. 2020; (7): 69
[Pubmed] | [DOI]
21 The Effects of the Marine-Derived Polysaccharides Laminarin and Chitosan on Aspects of Colonic Health in Pigs Challenged with Dextran Sodium Sulphate
Ruth Rattigan,John V. O’Doherty,Stafford Vigors,Marion T. Ryan,Rocco S. Sebastiano,John J. Callanan,Kevin Thornton,Gaurav Rajauria,Lekha M. Margassery,Alan D. W. Dobson,Niall D. O’Leary,Torres Sweeney
Marine Drugs. 2020; 18(5): 262
[Pubmed] | [DOI]
22 Differences in Gut Microbiota in Patients With vs Without Inflammatory Bowel Diseases: A Systematic Review
Rapat Pittayanon,Jennifer T. Lau,Grigorios I. Leontiadis,Frances Tse,Yuhong Yuan,Michael Surette,Paul Moayyedi
Gastroenterology. 2019;
[Pubmed] | [DOI]
23 Dynamic gut microbiome changes following regional intestinal lymphatic obstruction in primates
F. Becker,F.N.E. Gavins,J. Fontenot,P. Jordan,J.Y. Yun,R. Scott,P.R. Polk,R.E. Friday,M. Boktor,M. Musso,E. Romero,S. Boudreaux,J. Simmons,D.L. Hasselschwert,J.E. Goetzmann,J. Vanchiere,U. Cvek,M. Trutschl,P. Kilgore,J.S. Alexander
Pathophysiology. 2019;
[Pubmed] | [DOI]
24 Intestinal Inflammation Modulates the Epithelial Response to Butyrate in Patients With Inflammatory Bowel Disease
Elena Ferrer-Picón,Isabella Dotti,Ana M Corraliza,Aida Mayorgas,Miriam Esteller,José Carlos Perales,Elena Ricart,Maria C Masamunt,Anna Carrasco,Eva Tristán,Maria Esteve,Azucena Salas
Inflammatory Bowel Diseases. 2019;
[Pubmed] | [DOI]
25 Interplay Between the Host, the Human Microbiome, and Drug Metabolism
Robert G. Nichols,Jeffrey M. Peters,Andrew D. Patterson
Human Genomics. 2019; 13(1)
[Pubmed] | [DOI]
26 Identification of Specific Oral and Gut Pathogens in Full Thickness Colon of Colitis Patients: Implications for Colon Motility
Vasudevan Dinakaran,Sammed N. Mandape,Kristina Shuba,Siddharth Pratap,Shruti S. Sakhare,Mohammad Ali Tabatabai,Duane T. Smoot,Cherae M. Farmer-Dixon,Lakshmyya N. Kesavalu,Samuel Evans Adunyah,Janet Hayes Southerland,Pandu R. Gangula
Frontiers in Microbiology. 2019; 9
[Pubmed] | [DOI]
27 The role of intestinal microbiota in the pathogenesis of colorectal carcinoma
Jozef Kuzma,Dittmar Chmelar,Michal Hájek,Alexandra Lochmanová,Ivan Cižnár,Miroslav Rozložník,Miloslav Klugar
Folia Microbiologica. 2019;
[Pubmed] | [DOI]
28 Hydrogen sulfide-mediated resistance against water avoidance stress-induced gastritis by maintenance of gastric microbial homeostasis
Yingnan Han,Ya Li,Zhekai Hu,Xiao Wang,Junze Liu,Xue Ren,Yanbo Yu,Yan Li,Wenjuan Li,Yundong Sun
MicrobiologyOpen. 2019;
[Pubmed] | [DOI]
29 Comparison of gut microbiome between low fiber and high fat diet fed mice
Nakwon Hwang,Taekil Eom,Tatsuya Unno
Journal of Applied Biological Chemistry. 2018; 61(2): 165
[Pubmed] | [DOI]
30 Modulation of faecal metagenome in Crohn’s disease: Role of microRNAs as biomarkers
María Rojas-Feria,Teresa Romero-García,Jose Ángel Fernández Caballero-Rico,Helena Pastor Ramírez,Marta Avilés-Recio,Manuel Castro-Fernandez,Natalia Chueca Porcuna,Manuel Romero-G?mez,Federico García,Lourdes Grande,José A Del Campo
World Journal of Gastroenterology. 2018; 24(46): 5223
[Pubmed] | [DOI]
31 A High-Throughput Organoid Microinjection Platform to Study Gastrointestinal Microbiota and Luminal Physiology
Ian A. Williamson,Jason W. Arnold,Leigh Ann Samsa,Liam Gaynor,Matthew DiSalvo,Jordan L. Cocchiaro,Ian Carroll,M. Andrea Azcarate-Peril,John F. Rawls,Nancy L. Allbritton,Scott T. Magness
Cellular and Molecular Gastroenterology and Hepatology. 2018;
[Pubmed] | [DOI]
32 Microbiome, gut dysbiosis and inflammatory bowel disease: That moment when the function is more important than taxonomy
S. I. Sitkin,T. Ya. Vakhitov,E. V. Demyanova
Almanac of Clinical Medicine. 2018; 46(5): 396
[Pubmed] | [DOI]
33 TaqMan real-time RT-PCR assay for detecting Japanese encephalitis virus in swine blood samples and mosquitoes
P. B. Pantawane,H. Dhanze,G. V. P. P. S. Ravi Kumar,Grace M. R.,N. C. Dudhe,K. N. Bhilegaonkar
Animal Biotechnology. 2018; : 1
[Pubmed] | [DOI]
34 Gut Microbiota Offers Universal Biomarkers across Ethnicity in Inflammatory Bowel Disease Diagnosis and Infliximab Response Prediction
Youlian Zhou,Zhenjiang Zech Xu,Yan He,Yunsheng Yang,Le Liu,Qianyun Lin,Yuqiang Nie,Mingsong Li,Fachao Zhi,Side Liu,Amnon Amir,Antonio González,Anupriya Tripathi,Minhu Chen,Gary D. Wu,Rob Knight,Hongwei Zhou,Ye Chen,Danilo Ercolini
mSystems. 2018; 3(1): e00188-17
[Pubmed] | [DOI]
35 Ursodeoxycholic Acid and Its Taurine- or Glycine-Conjugated Species Reduce Colitogenic Dysbiosis and Equally Suppress Experimental Colitis in Mice
Lien Van den Bossche,Pieter Hindryckx,Lindsey Devisscher,Sarah Devriese,Sophie Van Welden,Tom Holvoet,Ramiro Vilchez-Vargas,Marius Vital,Dietmar H. Pieper,Julie Vanden Bussche,Lynn Vanhaecke,Tom Van de Wiele,Martine De Vos,Debby Laukens,Christopher A. Elkins
Applied and Environmental Microbiology. 2017; 83(7)
[Pubmed] | [DOI]
36 In Silico Analysis of Putrefaction Pathways in Bacteria and Its Implication in Colorectal Cancer
Harrisham Kaur,Chandrani Das,Sharmila S. Mande
Frontiers in Microbiology. 2017; 8
[Pubmed] | [DOI]
37 Vitamin A deficiency in mice alters host and gut microbial metabolism leading to altered energy homeostasis
Yuan Tian,Robert G. Nichols,Jingwei Cai,Andrew D. Patterson,Margherita T. Cantorna
The Journal of Nutritional Biochemistry. 2017;
[Pubmed] | [DOI]
38 Colorectal cancer-inflammatory bowel disease nexus and felony of Escherichia coli
Abdul Arif Khan,Zakir Khan,Abdul Malik,Mohd Abul Kalam,Phillip Cash,Mohd. Tashfeen Ashraf,Aws Alshamsan
Life Sciences. 2017; 180: 60
[Pubmed] | [DOI]
39 Understanding the Gut Microbiota in Inflammatory and Functional Gastrointestinal Diseases
Johanna Sundin,Lena Öhman,Magnus Simrén
Psychosomatic Medicine. 2017; 79(8): 857
[Pubmed] | [DOI]
40 Intestinal Bacteria Composition and Translocation of Bacteria in Inflammatory Bowel Disease
Spyros Vrakas,Konstantinos C. Mountzouris,George Michalopoulos,George Karamanolis,George Papatheodoridis,Charalampos Tzathas,Maria Gazouli,Leonardo A. Sechi
PLOS ONE. 2017; 12(1): e0170034
[Pubmed] | [DOI]
41 The Probiotic VSL#3 Modulates Colonic Macrophages, Inflammation, and Microflora in Acute Trinitrobenzene Sulfonic Acid Colitis
Raymond A. Isidro,Abdon Lopez,Myrella L. Cruz,Mayra I. Gonzalez Torres,Gladys Chompre,Angel A. Isidro,Caroline B. Appleyard
Journal of Histochemistry & Cytochemistry. 2017; 65(8): 445
[Pubmed] | [DOI]
42 Emerging Technologies for Gut Microbiome Research
Jason W. Arnold,Jeffrey Roach,M. Andrea Azcarate-Peril
Trends in Microbiology. 2016;
[Pubmed] | [DOI]
43 Study of duodenal bacterial communities by 16S rRNA gene analysis in adults with active celiac diseasevsnon-celiac disease controls
E. Nistal,A. Caminero,A.R. Herrán,J. Pérez-Andres,S. Vivas,J.M. Ruiz de Morales,L.E. Sáenz de Miera,J. Casqueiro
Journal of Applied Microbiology. 2016; 120(6): 1691
[Pubmed] | [DOI]
44 Permissive/Protective Interplay of Microbiota with T Cell Adaptive Immune Response in Colon Cancer
Zahra Mojtahedi,Somayeh Rezaeifard,Zahra Faghih
Annals of Colorectal Research. 2016; 4(4)
[Pubmed] | [DOI]
45 Gut microbiome in children with enthesitis-related arthritis in a developing country and the effect of probiotic administration
A. Aggarwal,A. N. Sarangi,P. Gaur,A. Shukla,Rakesh Aggarwal
Clinical & Experimental Immunology. 2016;
[Pubmed] | [DOI]
46 Gut inflammation and microbiome in spondyloarthritis
Jayakanthan Kabeerdoss,Pulukool Sandhya,Debashish Danda
Rheumatology International. 2015;
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article
   Material & Methods
    Article Figures
    Article Tables

 Article Access Statistics
    PDF Downloaded1031    
    Comments [Add]    
    Cited by others 46    

Recommend this journal